Ivantis Stock

ivantisinc.comHealthcare / Other HealthcareFounded: 1900Funding to Date: $132.88MM

lvantis is a healthcare company committed to expanding patient treatment and improving outcomes through new and innovative minimally invasive glaucoma surgical (MIGS) solutions, the fastest growing segment of the ophthalmology market.

Register for Details

For more details on financing and valuation for Ivantis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ivantis.

Register Today

Team

Management Team

Dave Van Meter
Chairman, President & Chief Executive Officer
Brandon Lorry
Senior Director
Kenneth Galt
Vice President, Research & Development
Brett Trauthen
Chief Scientific Officer

Board Members

Ben Gust
GBS Venture Partners
Albert Graf
New Enterprise Associates
Lincoln Chee Wang Jin
Randy Alexander
Brant Heise
MemorialCare Innovation Fund
Dave Van Meter
James Pade
Tara Butler MD
Ascension Ventures
Yoh-Chie Lu
Vertex Ventures HC
Ali Behbahani MD
New Enterprise Associates
Douglas Roeder
Delphi Ventures
John Nehra
New Enterprise Associates
Peter Kolchinsky Ph.D
RA Capital Management
Thong Yuen Poon Ph.D
EDBI

Other companies like Ivantis in the Other Healthcare sector

Sector
Last Round Est. Valuation
$165MM
Sector
Last Round Est. Valuation
$368.08MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$125MM
Sector
Last Round Est. Valuation
$140MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$173.59MM
Sector
Last Round Est. Valuation
$300.91MM

News Highlights

Ivantis Raises $25M in Series C Funding |FinSMEs
Ivantis Inc., an Irvine, CA-based developer of a device designed to lower eye pressure for glaucoma patients, closed a $25m Series C financing. The round was led by new investor RA Capital Management, with participation from new investor Mérieux Développement, as well as existing investors. The company intends to use the funds for US commercialization …
Updated on: Oct 2, 2023